Mereo BioPharma
MREO
90 hedge funds and large institutions have $250M invested in Mereo BioPharma in 2025 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 27 increasing their positions, 21 reducing their positions, and 14 closing their positions.
100% more call options, than puts
Call options by funds: $3.5M | Put options by funds: $1.75M
29% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 21
0.88% less ownership
Funds ownership: 14.85% → 13.97% (-0.88%)
7% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 14
1% less funds holding
Funds holding: 91 → 90 (-1)
38% less capital invested
Capital invested by funds: $403M → $250M (-$153M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$15.9M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$7.7M |
| 3 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$6.19M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$3.1M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$19.8M |
| 2 |
Millennium Management
New York
|
-$10.1M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$8.25M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$4.85M |
| 5 |
Morgan Stanley
New York
|
-$3.89M |
MREO Hedge Fund Activity: Q1 2025 in Review
90 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q1 2025, worth a combined $250M — down 38% from $403M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of MREO and 13 opened new positions — a net loss of 1 holder — while 21 trimmed existing stakes and 27 added.
The largest buyer was Janus Henderson Group, adding an estimated $15.9M. The largest seller was Adage Capital Partners, cutting an estimated $19.8M.
- 90 institutional investors held Mereo BioPharma (MREO) as of Q1 2025, down from 91 in Q4 2024.
- Funds reported $250M of Mereo BioPharma stock for Q1 2025, down 38% quarter-over-quarter.
- 13 funds opened new Mereo BioPharma positions in Q1 2025 and 14 closed out, a net change of -1 holder.
- The largest Mereo BioPharma buyer in Q1 2025 was Janus Henderson Group, an estimated $15.9M added.
- The largest Mereo BioPharma seller in Q1 2025 was Adage Capital Partners, an estimated $19.8M sold.
Based on aggregated 13F filings for Q1 2025.